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Abstract: There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We ana-
lyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme 
for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten 
single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron 
boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms 
and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies  
between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on   
haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis,  
and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene 
variants may not be a factor in vulnerability to METH dependence/psychosis. 
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse. 
INTRODUCTION 
  Methamphetamine (METH) is a psychomotor stimulant 
with high liability for abuse, and METH abuse has become a 
very serious social problem in Japan [1]. Chronic METH 
abusers have been shown to have persistent dopaminergic 
deficits [2, 3]. In animals, amphetamine elevates extracellu-
lar dopamine levels in the mesolimbic circuits [4, 5]. There 
is growing evidence that serotonergic systems modulate do-
paminergic neurotransmission. For example, the mesocorti-
colimbic dopamine system is under inhibitory control by the 
serotonin system, which exerts its actions via serotonin re-
ceptor subtypes [6, 7]. 
  Acute and chronic administration of METH markedly 
decreases the activity of tryptophan hydroxylase (TPH) [8, 9], 
the rate-limiting enzyme in the biosynthesis of serotonin   
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[10]. TPH2 (or neuronal TPH) was identified as a second 
isoform of TPH in 2003 [11, 12]. In contrast to TPH1, which 
is expressed predominantly in the pineal gland and the pe-
riphery, TPH2 mRNA is expressed in the raphe nuclei [11]. 
Since the identification of TPH2, there have been numerous 
association analyses between TPH2 gene variants and psy-
chiatric diseases. For example, associations have been ob-
served between TPH2 variants and bipolar disorder [13-18], 
suicidal behavior in major depression [19-21], the response 
to selective serotonin reuptake inhibitors (fluoxetine and/or 
citalopram) [22, 23] and emotional regulation in healthy sub-
jects [24-28]. These reports indicate that polymorphic vari-
ants in the TPH2 gene may have a role in the pathophysiol-
ogy of a wide range of psychiatric disorders and emotional 
regulation. A recent study of heroin addiction also showed 
an association with TPH2 variants in Hispanics and African-
Americans [29]. 
  The purpose of this study was (1) to identify novel se-
quence variations in all coding exons as well as exon-intron 
boundaries of the TPH2 gene in Japanese, and (2) to investi-
gate whether these polymorphisms and/or haplotypes were 
associated with METH dependence/psychosis. TPH2 Gene Association with METH Abuse  Current Neuropharmacology, 2011, Vol. 9, No. 1    177 
MATERIALS AND METHODS 
Subjects 
  One-hundred sixty-two unrelated patients with METH 
dependence/psychosis (130 males and 32 females; mean age 
37.4±12.0 years) meeting ICD-10-DCR criteria (F15.2 and 
F15.5) were used as case subjects; they were outpatients or 
inpatients of psychiatric hospitals. The 243 control subjects 
(168 males and 75 females; mean age 35.4±11.5 years) were 
mostly medical staff members who had neither personal nor 
familial history of drug dependence or psychotic disorders, 
as verified by a clinical interview. All subjects were Japa-
nese, born and living in the northern Kyushu, Setouchi, Chu-
kyo, Tokai, and Kanto regions. This study was approved by 
the ethical committees of each institute of the Japanese Ge-
netics Initiative for Drug Abuse (JGIDA), and all subjects 
provided written informed consent for the use of their DNA 
samples for this research [30]. After informed consent was 
obtained, blood samples were drawn and genomic DNA was 
extracted by the phenol/chloroform method.  
Defining Variants of the TPH2 Gene 
  Initially, 16 METH dependent/psychotic patient samples 
were used to identify nucleotide variants within the TPH2 
gene (GenBank accession no. AC090109). Exons 1 to 11 and 
exon-intron boundaries were amplified by polymerase chain 
reaction (PCR) using a thermal cycler (Astec, Fukuoka, Japan), 
and the products were sequenced in both directions using 
BigDye terminators (Applied Biosystems, Foster City, CA) 
by an ABI Genetic analyzer 3100 (Applied Biosystems). 
  Genotyping of each polymorphism except in exon 11 was 
performed by PCR amplification using the relevant primers 
listed in Table 1 followed by sequencing using the same 
primers in both directions. Genotyping of polymorphisms in 
exon 11 was performed by PCR amplification using 9F and 
11R primers followed by sequencing using 10F, 11F, and 
11R primers. 
Patient Subgroups 
  For the clinical category analysis, the patients were di-
vided into two subgroups by three different clinical features. 
(A) Latency of psychosis from first METH intake: less than 
3 years or more than 3 years. The course of METH psychosis 
varied among patients, with some patients showing psycho-
sis sooner after the first METH intake, as previously reported 
[30, 31]. Because the median latency was three years, this 
time point was used as the cutoff in defining the two groups. 
(B) Duration of psychosis after the last METH intake: tran-
sient (<1 month) or prolonged ( > =1 month). Some patients 
showed continuous psychotic symptoms even after METH 
discontinuation, as previously reported [30, 31]. Patients 
with the transient type showed a reduction of psychotic 
symptoms within one month after the discontinuation   
of METH consumption and the beginning of treatment with 
neuroleptics. Patients with the prolonged type showed a   
psychotic symptoms continued for more than one month 
even after the discontinuation of METH consumption and 
the beginning of neuroleptic treatment. (C) Spontaneous   
relapse: present or not. It has been well documented that 
once METH psychosis has developed, patients in the remis-
sion phase are liable to spontaneous relapse without recon-
sumption [30, 31]. 
Statistical Analysis 
  The Hardy-Weinberg equilibrium of genotypic frequen-
cies in each SNP was tested by the chi-square test. The level 
of statistical significance was set at = 0.05. The allelic and 
genotypic frequencies of patients and control groups were 
compared using the chi-square test. Locus by locus linkage 
disequilibrium (LD) was evaluated by D’ and r
2, which were 
calculated by the haplotype frequencies using the appropriate 
formula in the Excel program. A global test of differentiation 
among samples based on haplotype frequencies was per-
formed using the Arlequin program available from http:// 
anthropologie.unige.ch/arlequin [32]. 
Table 1.  Primers Used in this Study 
Exon Forward  Reverse 
Exon 1  1F  CCT TAT GTA TTG TTC TCC ACC ACC  1R  GTT GAG CAC GCA GTG ATT GGC ACA 
Exon 2  2F  CCA CTA GAT GAT GTC TTA GAC CAT  2R  CTG ACC TCC TAA CCT GGC AAT AGT 
Exon 3,4  3F  GTA CTT GGC ACC TTG CTT AAG ATG  3R  TGG AAG TCT GCT CTC AGT TAT GGG 
Exon 5  4F  GCT CAA CTA AGC CAT TCT GCT TAC  4R  GTA GCA CTT GGC ATG TGG CTC ACA 
Exon 6  5F  GAT CCT TTC AGA CGC TCA TGT GCT  5R  CAT ACT CAT GTA GCC CAG CAC AGC 
Exon 7  6F  GTG CGG TAA GCA TCA CTT TCG ATT  6R  CAG ATG AGG AGT CTG ATC CTT CAG 
Exon 8  7F  GAA GTC CCA GCA TTG ATG AAC TGT  7R  GGC TAA GCT GAG TAA TTC TGA CAG 
Exon 9  8F  CAG GAA GCG TAA GAC TCT TAG TAG  8R  GTC AGT AGG ATC ACT GCT AGC TCA 
Exon 10, 11  9F  CCT GCA CAC AGG AGA GTT CCA TAT  9R  CAT GCT GGC AAC AAC ATA GTT CCA 
  10F  CAA TCC CTA CAC ACA GAG TAT TGA  10R  CAT TCC AAC TGC TGT GTT ACC TCA 
  11F  GAT CTA AGC CTT TCC TCT GTG TTC  11R  GAC ACA GAA ACA CAT GCA AGC ACT 178    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kobayashi et al. 
RESULTS 
  To identify polymorphisms in the TPH2 gene, all coding 
exons (1 to 11) and exon-intron boundaries were analyzed 
using genomic DNA from 16 Japanese METH-
dependent/psychotic subjects. Ten single nucleotide poly-
morphisms (SNPs) and two insertion / deletion polymor-
phisms were identified. One polymorphism, Exon11+(C3) 
500(C2), was novel (Table 2). Two SNPs, rs7305115 
(Exon7+A131G) and rs4290270 (Exon9+A57T), were syn-
onymous mutations and Eon2+C18A was a non-synonymous 
mutation. Three linkage disequilibrium (LD) regions were 
found, rs11178998 (Exon1-A42G) to rs41265611 (IVS1+60 
(I/D)), rs11179003 (IVS4+C4821T) to rs10879348 (IVS6+ 
G144A), and rs4760816 (IVS6+C6106T) to rs7305115 
(Exon7+A131G), in the sense that all genotypic patterns in 
all 16 samples analyzed were the same. Each one of the 
SNPs was chosen and a total of nine SNPs were genotyped 
for further analysis. LD mapping was analyzed by using 
SNPs having minor allele frequencies of over 10% in both 
samples (Table 4). LD was observed from rs17110566 
(IVS6+G152A) to rs17110747 (Exon11+G654A) and from 
rs4290270 (Exon9+A57T) to rs41317114 (IVS11+G128C) 
(Fig. 1 and Table 3).  
  Association analyses were performed on these nine po-
lymorphic positions using 162 METH dependent/psychotic 
patients and 243 controls. Genotypic frequencies in these 
Table 2.  TPH2 Gene Variants Found in the Japanese Population 
Position
1) Location  rs  Number
2) SNP  Name  Variation  Function 
30029 5'  side  rs11178998  Exon1-A42G  A/G   
30241 Intron  1  rs41265611  IVS1+60(I/D)  TCT/del   
32694 Exon  2    Exon2+C18A
3) C/A  nonsynonymous  (Ser41Tyr) 
40601 Intron  4  rs11179003  IVS4+C4821T  C/T   
63953 Intron  6  rs10879348  IVS6+G144A  G/A   
63961 Intron  6  rs17110566  IVS6+G152A  G/A   
69915 Intron  6  rs4760816 IVS6+C6106T  C/T   
70176  Exon 7  rs7305115  Exon7+A131G  A/G  synonymous (Pro312Pro) 
113549  Exon 9  rs4290270  Exon9+A57T  A/T  synonymous (Ala375Ala) 
123114 Exon  11    Exon11+(C3)500(C2)  C3/C2   
123268 Exon  11  rs17110747 Exon11+G654A  G/A   
123663 3'  side  rs41317114 IVS11+G128C  G/C   
1) Position: nucleotide position number in the NCBI nucleotide database under accession number AC090109. 
2) rs number: NCBI SNP database.
 3) This SNP was reported as C2755A 
[14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Location and linkage disequilibrium mapping of the TPH2 gene polymorphisms. All the coding exons and their regions were taken 
from the NCBI database under accession number AC090109. Red ovals indicate the polymorphic positions, solid black lines the analyzed 
regions, and solid red lines the LD block. 
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Table 3.  Linkage Disequilibrium Mapping of the TPH2 Gene 
  
  
rs17110566 
(IVS6+G152A) 
rs4760816 
(IVS6+C6106T) 
rs4290270 
(Exon9+A57T) 
rs17110747 
(Exon11+G654A) 
rs41317114 
(IVS11+G128C) 
rs17110566      0.9392 0.6138 0.8581 0.0348 
rs4760816  0.9724    0.7301  0.9253  0.0092 
rs4290270  0.5262 0.5881      0.9284 0.6051 
rs17110747 0.8437  0.7885  0.9774      0.9399 
rs41317114  0.0111 0.2179 0.6284 0.9123     
                 r
2 
 
 
 
 
 
D’ 
D' and r
2 values for Control samples are shown in the upper right and lower left, respectively.  
Table 4.  Genotypic and Allelic Distribution of the TPH2 gene SNPs in the METH Dependent/Psychotic Patients and the Control 
Groups 
SNP  Group  Genotype (%)  P  Allele (%)  P 
   A/A  A/G  G/G     A  G    
METH  130 (80%)  29 (18%)  3 (2%)  289 (89%)  35 (11%) 
rs11178998  
(Exon1-A42G) 
Control  197 (81%)  46 (19%)  0 (0%) 
0.102  
440 (91%)  46 (9%) 
0.617 
   C/C  C/A  A/A     C  A    
METH  146 (90%)  16 (10%)  0 (0%)  308 (95%)  16 (5%) 
Exon2+C18A 
Control  222 (91%)  21 (9%)  0 (0%) 
0.914  
465 (96%)  21 (4%) 
0.807 
   G/G  G/A  A/A     G  A    
METH  136 (84%)  26 (16%)  0 (0%)  298 (92%)  26 (8%) 
rs10879348  
(IVS6+G144A) 
Control  206 (85%)  37 (15%)  0 (0%) 
0.975  
449 (92%)  37 (8%) 
0.920 
   G/G  G/A  A/A     G  A    
METH  123 (76%)  35 (22%)  4 (2%)  281 (87%)  43 (13%) 
rs17110566  
(IVS6+G152A) 
Control  173 (71%)  64 (26%)  6 (2%) 
0.552  
410 (84%)  76 (16%) 
0.406 
   C/C  C/T  T/T     C  T    
METH  28 (17%)  85 (52%)  49 (30%)  141 (44%)  183 (56%) 
rs4760816  
(IVS6+C6106T) 
Control  57 (23%)  121 (50%)  65 (27%) 
0.314  
235 (48%)  251 (52%) 
0.200 
   A/A  A/T  T/T     A  T    
METH  29 (18%)  80 (49%)  53 (33%)  138 (43%)  186 (57%) 
rs4290270  
(Exon9+A57T) 
Control  49 (20%)  115 (47%)  79 (33%) 
0.840  
213 (44%)  273 (56%) 
0.777 
   C3/C3  C3/C2  C2/C2     C3  C2    
METH  159 (98%)  3 (2%)  0 (0%)  321 (99%)  3 (1%) 
Exon11+(C3)500(C2) 
Control  242 (100%)  1 (0%)  0 (0%) 
0.357  
485 (100%)  1 (0%) 
0.357 
   G/G  G/A  A/A     G  A    
METH  92 (57%)  63 (39%)  7 (4%)  247 (76%)  77 (24%) 
rs17110747 
(Exon11+G654A) 
Control  136 (56%)  95 (39%)  12 (5%) 
0.956  
367 (76%)  119 (24%) 
0.888 
   G/G  G/C  C/C     G  C    
METH  119 (73%)  38 (23%)  5 (3%)  276 (85%)  48 (15%) 
rs41317114 
(IVS11+G128C) 
Control  187 (77%)  50 (21%)  6 (2%) 
0.719  
424 (87%)  62 (13%) 
0.462 180    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kobayashi et al. 
Table 5.  Genotypic Distribution of the TPH2 Gene SNPs in Clinically Subcategorized METH Subjects 
SNP Groups  Subgroup  N  Genotype  P 
            G  G/A  A    
Control        243  173  64  6    
<3 years  64  53  10  1  0.172  Latency of Psychosis 
≧3 years  67  47  18  2  0.966 
Transient (<1 month)  87  67  17  3  0.421  Prognosis of Psychosis 
Prolonged (≧1 month)  52  38  13  1  0.951 
Not present  101  78  21  2  0.517 
rs17110566 
(IVS6+G152A) 
METH 
Spontaneous Relapse 
Present 56  42  12  2  0.694 
            C  C/T  T    
Control        243  57  121  65    
<3 years  64  13  35  16  0.771  Latency of Psychosis 
≧3 years  67  9  35  23  0.165 
Transient (<1 month)  87  15  39  33  0.125  Prognosis of Psychosis 
Prolonged (≧1 month)  52  7  34  11  0.107 
Not present  101  19  51  31  0.577 
rs4760816 
(IVS6+C6106T) 
METH 
Spontaneous Relapse 
Present 56  8  30  18  0.306 
            A  A/T  T    
Control        243  49  115  79    
<3 years  64  8  35  21  0.338  Latency of Psychosis 
≧3 years  67  13  32  22  0.990 
Transient (<1 month)  87  16  37  34  0.541  Prognosis of Psychosis 
Prolonged (≧1 month)  52  6  34  12  0.058 
Not present  101  17  52  32  0.712 
rs4290270 
(Exon9+A57T) 
METH 
Spontaneous Relapse 
Present 56  10  27  19  0.923 
            G  G/A  A    
Control        243  136  95  12    
<3 years  64  35  28  1  0.438  Latency of Psychosis 
≧3 years  67  37  26  4  0.947 
Transient (<1 month)  87  52  31  4  0.827  Prognosis of Psychosis 
Prolonged (≧1 month)  52  26  25  1  0.366 
Not present  101  57  41  3  0.712 
rs17110747 
(Exon11+G654A) 
METH 
Spontaneous Relapse 
Present 56  32  21  3  0.970 
            G  G/C  C    
Control        243  187  50  6    
<3 years  64  49  15  0  0.411  Latency of Psychosis 
≧3 years  67  48  16  3  0.552 
Transient (<1 month)  87  65  19  3  0.852  Prognosis of Psychosis 
Prolonged (≧1 month)  52  38  13  1  0.767 
Not present  101  77  21  3  0.966 
rs41317114 
(IVS11+G128C) 
METH 
Spontaneous Relapse 
Present 56  38  17  1  0.282 
N: Number of samples. 
P: Significance values between the METH subjects and the controls. TPH2 Gene Association with METH Abuse  Current Neuropharmacology, 2011, Vol. 9, No. 1    181 
 
SNPs were within the Hardy-Weinberg expectations. No 
significant differences were found in the allelic or genotypic 
frequencies of these SNPs between the METH depend-
ent/psychotic patients and the controls (Table 4). Since the 
minor allele frequency of the Exon11+(C3)500(C2) SNP 
was less than 1% in controls, this SNP was excluded from 
the haplotype analysis. No significant difference (P=0.448) 
was observed in a differentiation test between all pairs of 
samples based on haplotype frequencies by the Arlequin 
program. 
  Subcategory analyses were conducted on the clinical pa-
rameters (latency of psychosis, prognosis of psychosis, and 
spontaneous relapse). SNPs having minor allele frequencies 
of over 10% in both samples were used for this analysis: 
rs17110566 (IVS6+G152A), rs4760816 (IVS6+C6106T), 
rs4290270 (Exon9+A57T), rs17110747 (Exon11+G654A), 
and IVS11+G129C. No significant associations with clinical 
parameters were observed (Table 5). 
DISCUSSION 
 We  analyzed  the  TPH2 gene polymorphisms in a Japa-
nese population and found ten SNPs and two inser-
tion/deletion variants, among which one variant was novel. 
However, we failed to identify any variants or haplotypes in 
the TPH2 gene examined in this study which were associated 
with METH dependence/psychosis. 
  Exon2+C18A is a nonsynonymous SNP and the corre-
sponding amino acid is changed from Ser to Tyr at peptide 
position 41 (S41Y). This SNP was reported as C2755A by 
Lin and colleagues in a Han Chinese population [14]. They 
transfected plasmids containing full-lengthTPH2 protein–
encoding sequences with two alternative alleles into SH-
SY5Y cells and found that the amount of serotonin in SH-
SY5Y cells expressing the 41Y allele was about 36% lower 
than in cells expressing the 41S allele. Despite the strong 
scientific rationale for studying polymorphisms in the TPH2 
gene in METH dependence/psychosis, we could not identify 
any variants or haplotypes associated with the phenotype. 
These results were comparable to those for cocaine use. Both 
cocaine and METH increase extracellular dopamine in the 
brain, and increased dopamine in the nucleus accumbens is 
thought to underlie the reinforcing effects of drugs of abuse 
[5, 33]. The association of cocaine dependence in subjects of 
African descent with TPH2 SNPs was analyzed by Dahl and 
colleagues, but they failed to identify any SNPs that were 
associated with the cocaine-dependent phenotype [34]. The 
disparity between these results and the previously reported 
results for heroin addiction [29] suggest that the TPH2 gene 
has little effect in psychostimulants with the characteristics 
of indirect dopaminergic agonists. 
  Our results indicate that the TPH2 gene variations may 
not be vulnerability factors in METH dependence/psychosis, 
and indeed that they are likely to make a small or no contri-
bution to the development of METH dependence/psychosis. 
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